- Home
- MTNB vs CMND Comparison
MTNB vs CMND Comparison
Compare MTNB & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | CMND |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.6M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTNB | CMND |
|---|---|---|
| Price | $2.74 | $6.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 341.7K | 146.9K |
| Earning Date | 08-13-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.07 |
| 52 Week High | $3.16 | $7.16 |
Technical Indicators
Market Signals| Indicator | MTNB | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 74.24 | 90.06 |
| Support Level | $0.39 | $0.65 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.28 | 0.35 |
| MACD | 0.10 | 0.67 |
| Stochastic Oscillator | 87.33 | 91.56 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.